MenopauseNCT01633814
Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women
A study testing Transdermal estradiol in people with Menopause and Aging, run by University of Missouri-Columbia at 1 site in United States.
Trial summary
Older women have an exaggerated increase in blood pressure during exercise. However, the reasons for this are unclear. It is important to investigate this phenomenon because a greater blood pressure response to exercise has been associated with an increased risk of stroke and mortality in otherwise healthy… Read more about this study
- Who is it for?
- Ages 18 to 80 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Menopause, Aging, Blood Pressure
- What is being tested?
- Transdermal estradiol
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 4 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2011to Aug 2015
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- We plan to study female subjects of all ethnic backgrounds ranging in age from 18 to 80 years. Only healthy, normotensive individuals not taking medications will be included in this study.
- All postmenopausal women will be at least 4 years post menopause to avoid the potential for perimenopausal interference with study results
Who cannot join
- Active cardiopulmonary disease
- Hypertension
- Diabetes
- Chronic Obstructive Pulmonary Disease with concurrent daily use of inhalers.
- Known liver disease
- Peripheral neuropathy
Show all 16Show fewer
- Chronic Kidney disease
- Pregnant women
- Any of the following contraindications to estrogen usage will cause exclusion:
- Personal or 1st degree relative (mother, sister, daughter) history of breast, ovarian, or uterine cancer
- Vaginal bleeding;
- Current thrombophlebitis or venous thromboembolic disorders including deep vein thrombosis or pulmonary embolus;
- Arterial thromboembolic disease such as stroke or myocardial infarction
- Migraine headaches
- Any previous intolerance to estrogen supplementation.
- Women who have smoked during the one-year period prior to enrollment.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Influence of Hormone Replacement on Neural Cardiovascular Control in Postmenopausal Women
Older women have an exaggerated increase in blood pressure during exercise. However, the reasons for this are unclear. It is important to investigate this phenomenon because a greater blood pressure response to exercise has been associated with an increased risk of stroke and mortality in otherwise healthy individuals. A unique aspect of aging in women is the profound change in hormone levels (i.e. estrogen and progesterone) associated with menopause. The influence of changes in estrogen and progesterone levels on the cardiovascular responses to exercise is poorly understood. However, it has been suggested that these hormones might change the responsiveness of the cardiovascular system. Possible mechanisms that could account for these changes are the arterial baroreflex and feedback from the exercising muscle (known as the exercise pressor reflex), both of which are known to powerfully modulate blood pressure during exercise. However, to date, few human studies have thoroughly examined the influence of changes in hormone levels on baroreflex function during exercise or the exercise pressor reflex in older women. As such, the purpose of this research project is to assess baroreflex function and the exercise pressor reflex in older women after transdermal estrogen and placebo.
Read the detailed description
Study Design Older postmenopausal women will be randomized, in a double-blinded crossover design, to receive (i) transdermal estradiol, delivery rate 100 µg day-1 plus oral placebo, or (ii) placebo patch plus oral placebo. The experimental measurements and procedures below will be performed before and 4 weeks after each treatment.
Experimental measurements:
Blood Pressure- A blood pressure cuff will be wrapped around the right arm to obtain blood pressure via a standard automated auscultometric device (Welch-Allyn). In addition, beat-by-beat blood pressure will be obtained via finger photoplethysmography (Finapress blood pressure monitor).
Heart Rate- Standard limb lead electrodes will be used to obtain heart rate measurements.
Respiration- An elastic band will be placed around the subject's abdomen to measure rate and depth of breathing.
Blood Samples- A venous catheter will be placed in the subjects arm for blood samples. For screening purposes measurements of glucose, electrolytes, cholesterol and triglycerides will be made. In addition, progesterone, estrogen and testosterone, will be assessed to verify hormonal status.
Sympathetic Nerve Activity- A tiny microelectrode will be placed in the peroneal nerve of the leg, located just below the knee on the outer part of the leg. Alternatively, the median nerve located at the inside of the elbow will be used. At these points the nerves are closest to the surface of the skin. The course of the nerve will be determined by electrically stimulating through the skin with a pencil shaped electrode. When the nerve is stimulated, involuntary twitching and/or tingling sensations of the foot or hand will occur. The twitching or tingling will disappear when the stimulation is stopped. Once the nerve is found, two tiny, sterile, microelectrodes will be inserted through the skin. One is a reference electrode placed just above the nerve site (2 cm) and the other is the recording electrode. The recording electrode is advanced into the nerve. When the tip of the electrode enters the nerve, the subject may briefly notice either pressure or tingling sensations. At this point, minor adjustments in the position of the electrode will be made until an optimal nerve signal is obtained.
Limb Blood Flow Measurements- Blood flow to the arm or leg may also be measured by using duplex Doppler ultrasound to non-invasively measure mean arterial blood velocity and diameter. Femoral or brachial blood velocity can be obtained by placing a Doppler flow probe on the skin over the common femoral artery distal to the inguinal ligament or the brachial artery, respectively. Ultrasound imaging of femoral artery or brachial artery diameter will be performed at a site matching that at which velocity is measured. The following formula is used to calculate blood flow: blood flow = π * radius2 * velocity.
Urine samples will be collected to measure specific gravity and pH using test strips.
Experimental Procedures:
Neck Pressure and Neck Suction- A padded neck collar will be fitted around the anterior portion of the subject's neck for the application of brief 5-second periods of neck pressure and neck suction. This allows the application of positive or negative pressure to the carotid sinus baroreceptors which are located in this region. The positive pressure will transiently cause these receptors to detect a decrease in blood pressure and thus cause an acute increase in heart rate, and blood pressure. The negative pressure will transiently cause these receptors to detect an increase in blood pressure and thus cause an acute decrease in heart rate, and blood pressure. This procedure has been used extensively to non-invasively assess baroreflex function in healthy subjects aged between 18-80 years. Nevertheless, in subjects over 50 years of age Doppler imaging will be performed to screen for atherosclerotic plaques within the carotid vessels to rule out carotid artery disease and determine the feasibility of performing neck pressure and neck suction.
Handgrip Exercise and Post Exercise Ischemia- The subject will be asked to perform handgrip exercise for either two minutes or until they feel like they cannot maintain the exercise (i.e., fatigue). Five seconds before stopping the exercise, a cuff around the upper arm will be inflated to impede blood flow for 2 minutes. This traps the metabolites that were produced during the exercise in the area of the muscle, which maintains stimulation of skeletal muscle metaboreceptor afferents. Since these metaboreceptor afferents contribute to the rise in blood pressure during exercise, continued stimulation of these receptors maintains a blood pressure response.
- Conditions
- Menopause, Aging, Blood Pressure
- Being tested
- Transdermal estradiol, Placebo
- Keywords
- Physiological Processes, Exercise, Hormone replacement therapy
- Medical subject headings
- Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transdermal estradiolDrug
Also called Elestrin
transdermal estradiol, delivery rate 100 µg day-1
PlaceboDrug
placebo patch.
| Study group | Role | What they receive |
|---|---|---|
| Transdermal estradiol | Experimental | Transdermal estradiol, delivery rate 100 µg day-1 Receives: Drug: Transdermal estradiol |
| Placebo | Placebo comparator | placebo patch. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Carotid Baroreflex Sensitivity (Bpm/mmHg)
Carotid baroreflex sensitivity will be measured using the application of neck pressure and neck suction. Briefly, a variable neck pressure collar will be placed around the anterior two thirds of the neck to change carotid sinus transmural pressure.
Measured: Within one week prior to and then after one month of transdermal estrogen alone, transdermal estrogen plus progesterone, progesterone alone and placebo.
Change in Exercise Pressor Reflex Responsiveness (Mean Blood Pressure Response (mmHg) and Muscle Sympathetic Nerve Activity Response (Burst Frequency) During Post Handgrip Ischemia.)
To estimate exercise pressor reflex responsiveness changes in blood pressure and muscle sympathetic nerve activity from rest to during a period of post handgrip ischemia will be used.
Measured: Within one week prior to and then after one month of transdermal estrogen alone, transdermal estrogen plus progesterone, progesterone alone and placebo.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jul 2012 (estimated)
- Study startSep 2011
- Primary completionAug 2015
- Study completionAug 2015
Why it stopped: PI left institution prior to completion of study. Data unavailable..
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for MenopauseStudies of the same condition, open and under way.
- More trials run by University of Missouri-ColumbiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 4 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Missouri-Columbia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Paul J Fadel, PhD, Principal investigator, University of Missouri-Columbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01633814
- Sponsor's protocol ID
- 1133919
- Status last verified
- Jun 2017
- First submitted
- 25 Jun 2012
- Last updated
- 10 Aug 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Influence of Hormone Replacement on Neural Cardiovascular Control in Postmenopausal Women
- ClinicalTrials.gov ID
- NCT01633814
- Acronym / sponsor ID
- 1133919
- Conditions
- Menopause, Aging, Blood Pressure
- Keywords
- Physiological Processes, Exercise, Hormone replacement therapy
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: PI left institution prior to completion of study. Data unavailable..
- Enrolment
- 4 participants (actual)
- Lead sponsor
- University of Missouri-ColumbiaUniversity, hospital or other
- Study start
- Sep 2011 (actual)
- Primary completion
- Aug 2015 (actual)
- Study completion
- Aug 2015 (actual)
- First posted
- 4 Jul 2012 (estimated)
- Results
- Posted 10 Aug 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Older women have an exaggerated increase in blood pressure during exercise. However, the reasons for this are unclear. It is important to investigate this phenomenon because a greater blood pressure response to exercise has been associated with an increased risk of stroke and mortality in otherwise healthy individuals. A unique aspect of aging in women is the profound change in hormone levels (i.e. estrogen and progesterone) associated with menopause. The influence of changes in estrogen and progesterone levels on the cardiovascular responses to exercise is poorly understood. However, it has been suggested that these hormones might change the responsiveness of the cardiovascular system. Possible mechanisms that could account for these changes are the arterial baroreflex and feedback from the exercising muscle (known as the exercise pressor reflex), both of which are known to powerfully modulate blood pressure during exercise. However, to date, few human studies have thoroughly examined the influence of changes in hormone levels on baroreflex function during exercise or the exercise pressor reflex in older women. As such, the purpose of this research project is to assess baroreflex function and the exercise pressor reflex in older women after transdermal estrogen and placebo.
Detailed description
Study Design Older postmenopausal women will be randomized, in a double-blinded crossover design, to receive (i) transdermal estradiol, delivery rate 100 µg day-1 plus oral placebo, or (ii) placebo patch plus oral placebo. The experimental measurements and procedures below will be performed before and 4 weeks after each treatment.
Experimental measurements:
Blood Pressure- A blood pressure cuff will be wrapped around the right arm to obtain blood pressure via a standard automated auscultometric device (Welch-Allyn). In addition, beat-by-beat blood pressure will be obtained via finger photoplethysmography (Finapress blood pressure monitor).
Heart Rate- Standard limb lead electrodes will be used to obtain heart rate measurements.
Respiration- An elastic band will be placed around the subject's abdomen to measure rate and depth of breathing.
Blood Samples- A venous catheter will be placed in the subjects arm for blood samples. For screening purposes measurements of glucose, electrolytes, cholesterol and triglycerides will be made. In addition, progesterone, estrogen and testosterone, will be assessed to verify hormonal status.
Sympathetic Nerve Activity- A tiny microelectrode will be placed in the peroneal nerve of the leg, located just below the knee on the outer part of the leg. Alternatively, the median nerve located at the inside of the elbow will be used. At these points the nerves are closest to the surface of the skin. The course of the nerve will be determined by electrically stimulating through the skin with a pencil shaped electrode. When the nerve is stimulated, involuntary twitching and/or tingling sensations of the foot or hand will occur. The twitching or tingling will disappear when the stimulation is stopped. Once the nerve is found, two tiny, sterile, microelectrodes will be inserted through the skin. One is a reference electrode placed just above the nerve site (2 cm) and the other is the recording electrode. The recording electrode is advanced into the nerve. When the tip of the electrode enters the nerve, the subject may briefly notice either pressure or tingling sensations. At this point, minor adjustments in the position of the electrode will be made until an optimal nerve signal is obtained.
Limb Blood Flow Measurements- Blood flow to the arm or leg may also be measured by using duplex Doppler ultrasound to non-invasively measure mean arterial blood velocity and diameter. Femoral or brachial blood velocity can be obtained by placing a Doppler flow probe on the skin over the common femoral artery distal to the inguinal ligament or the brachial artery, respectively. Ultrasound imaging of femoral artery or brachial artery diameter will be performed at a site matching that at which velocity is measured. The following formula is used to calculate blood flow: blood flow = π * radius2 * velocity.
Urine samples will be collected to measure specific gravity and pH using test strips.
Experimental Procedures:
Neck Pressure and Neck Suction- A padded neck collar will be fitted around the anterior portion of the subject's neck for the application of brief 5-second periods of neck pressure and neck suction. This allows the application of positive or negative pressure to the carotid sinus baroreceptors which are located in this region. The positive pressure will transiently cause these receptors to detect a decrease in blood pressure and thus cause an acute increase in heart rate, and blood pressure. The negative pressure will transiently cause these receptors to detect an increase in blood pressure and thus cause an acute decrease in heart rate, and blood pressure. This procedure has been used extensively to non-invasively assess baroreflex function in healthy subjects aged between 18-80 years. Nevertheless, in subjects over 50 years of age Doppler imaging will be performed to screen for atherosclerotic plaques within the carotid vessels to rule out carotid artery disease and determine the feasibility of performing neck pressure and neck suction.
Handgrip Exercise and Post Exercise Ischemia- The subject will be asked to perform handgrip exercise for either two minutes or until they feel like they cannot maintain the exercise (i.e., fatigue). Five seconds before stopping the exercise, a cuff around the upper arm will be inflated to impede blood flow for 2 minutes. This traps the metabolites that were produced during the exercise in the area of the muscle, which maintains stimulation of skeletal muscle metaboreceptor afferents. Since these metaboreceptor afferents contribute to the rise in blood pressure during exercise, continued stimulation of these receptors maintains a blood pressure response.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Transdermal estradiol | Experimental | Drug: Transdermal estradiolTransdermal estradiol, delivery rate 100 µg day-1 |
| Placebo | Placebo comparator | Drug: Placeboplacebo patch. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- We plan to study female subjects of all ethnic backgrounds ranging in age from 18 to 80 years. Only healthy, normotensive individuals not taking medications will be included in this study.
- All postmenopausal women will be at least 4 years post menopause to avoid the potential for perimenopausal interference with study results
Key exclusion criteria (16 listed)
- Active cardiopulmonary disease
- Hypertension
- Diabetes
- Chronic Obstructive Pulmonary Disease with concurrent daily use of inhalers.
- Known liver disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transdermal estradiolAlso: Elestrintransdermal estradiol, delivery rate 100 µg day-1 | Drug | Transdermal estradiol |
| Placeboplacebo patch. | Drug | Placebo |
Primary outcome
Change in Carotid Baroreflex Sensitivity (Bpm/mmHg)
Time frame: Within one week prior to and then after one month of transdermal estrogen alone, transdermal estrogen plus progesterone, progesterone alone and placebo.
Carotid baroreflex sensitivity will be measured using the application of neck pressure and neck suction. Briefly, a variable neck pressure collar will be placed around the anterior two thirds of the neck to change carotid sinus transmural pressure.
Change in Exercise Pressor Reflex Responsiveness (Mean Blood Pressure Response (mmHg) and Muscle Sympathetic Nerve Activity Response (Burst Frequency) During Post Handgrip Ischemia.)
Time frame: Within one week prior to and then after one month of transdermal estrogen alone, transdermal estrogen plus progesterone, progesterone alone and placebo.
To estimate exercise pressor reflex responsiveness changes in blood pressure and muscle sympathetic nerve activity from rest to during a period of post handgrip ischemia will be used.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Menopause
Recruiting
Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES)
Menopause, Perimenopause
Not yet recruiting
The Role of Diet Quality in Sleep Among Women in Postmenopause
Post Menopausal Women
Active, not recruitingPhase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
Infertility (IVF Patients)
Not yet recruiting
Effect of Hormone Replacement Therapy on Physiotherapy Outcomes in Postmenopausal Women With Frozen Shoulder
Frozen Shoulder, Adhesive Capsulitis
RecruitingObservational study
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Paul J Fadel, PhD principal investigator
University of Missouri-Columbia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transdermal estradiol in people with Menopause and Aging, run by University of Missouri-Columbia at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 10 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Aug 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Carotid Baroreflex Sensitivity (Bpm/mmHg) (time frame: Within one week prior to and then after one month of transdermal estrogen alone, transdermal estrogen plus progesterone, progesterone alone and placebo.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2017.